Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region
Studying Autosomal systemic lupus erythematosus
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- Monash University
- Principal Investigator
- Eric MorandMonash University
- Enrollment
- 5000 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2032
Study locations (20)
- Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia
- Department of Rheumatology, Flinders Medical Centre, Adelaide, South Australia, Australia
- School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing & Health Sciences, Clayton, Victoria, Australia
- Department of Rheumatology, St Vincent's Hospital (Melbourne), Fitzroy, Victoria, Australia
- Department of Rheumatology and Immunology, People's Hospital Peking University Health Science Center, Beijing, Western District, China
- Rheumatology and Immunology department, Peking University First Hospital, Beijing, Xicheng District, China
- Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Pok Fu Lam, Hong Kong
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Padjadjaran University/ Hasan Sadikin General Hospital, Bandung, West Java, Indonesia
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
- Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan
- Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
- Joint and Bone Center, University of Santo Tomas Hospital, Manila, Philippines
- University of the Philippines, Quezon City, Philippines
- Rheumatology Division, University Medical Cluster, National University Hospital, Singapore, Singapore
- Department of Rheumatology, Allergy & Immunology, Tan Tock Seng Hospital, Tan Tock Seng, Singapore
- +5 more locations on ClinicalTrials.gov
Collaborators
Flinders Medical Centre, Adelaide, AUSTRALIA · St. Vincent's Hospital, Melbourne, AUSTRALIA · Royal Adelaide Hospital, Adelaide, AUSTRALIA · The University of New South Wales · People's Hospital, Peking University Health Science Center, Beijing, CHINA · Peking University First Hospital, Beijing, CHINA · The University of Hong Kong · University of Padjadjaran, Bandung, INDONESIA · Tokyo Women's Medical University, JAPAN · University of Occupational and Environmental Health, JAPAN · Keio University, JAPAN · Hanyang University Hospital for Rheumatic Diseases, REPUBLIC OF KOREA · University of Santo Tomas Hospital, Philippines · National University Hospital, Singapore · Tan Tock Seng Hospital · Chang Gung Memorial Hospital · Taichung Veterans General Hospital · Chiang Mai University Hospital, THAILAND · Middlemore Hospital, New Zealand · North Shore Hospital, Auckland, NEW ZEALAND · Auckland District Health Board, Auckland, NEW ZEALAND · Teaching Hospital Kandy, SRI LANKA · University of the Philippines, Philippines
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03138941 on ClinicalTrials.govOther trials for Autosomal systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07447986To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus ErythematosusHangzhou Sumgen Biotech Co., Ltd.
- RECRUITINGPHASE1NCT07363590A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)Merck Sharp & Dohme LLC
- RECRUITINGPHASE3NCT07201129A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular TreatmentViatris Innovation GmbH
- RECRUITINGPHASE1NCT07276958A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)Eli Lilly and Company
- RECRUITINGPHASE1, PHASE2NCT07348055A Study of GR1803 in Systemic Lupus ErythematosusGenrix (Shanghai) Biopharmaceutical Co., Ltd.
- RECRUITINGNCT07000110Anifrolumab Malignancy and Serious Infections StudyAstraZeneca
- RECRUITINGPHASE1NCT07318259Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLEChongqing Precision Biotech Co., Ltd
- RECRUITINGPHASE1NCT07331467Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLEChongqing Precision Biotech Co., Ltd